Oxycodon / Naloxon Krugmann (Naloxone Hydrochloride, Oxycodone Hydrochloride)

Naloxone hydrochloride / Oxycodone hydrochloride, the active ingredient in Oxycodon / Naloxon Krugmann, is an opioid analgesic and opioid antagonist presented as a combination product for oral use. It is used to manage moderate to severe pain while reducing the risk of opioid‑induced respiratory depression in adult patients. GNH USA supplies Oxycodon / Naloxon Krugmann as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oxycodon / Naloxon Krugmann as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oxycodone/naloxone is an oral opioid analgesic formulation that acts on the central nervous system to treat pain conditions. - Chronic cancer pain: provides long‑lasting relief while limiting opioid‑related constipation. - Post‑operative pain: controls moderate to severe pain after surgery. - Severe non‑cancer chronic pain: offers sustained analgesia for patients who require strong opioids. - Acute severe pain episodes: delivers rapid pain control when other treatments are insufficient.

Side effects are related to both the opioid component and the peripheral opioid antagonist.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Constipation: reduced bowel motility, though less severe than with oxycodone alone. - Dizziness or light‑headedness: may occur during dose adjustments. - Drowsiness or fatigue: sedation common with opioid therapy. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing, especially with high doses or concurrent depressants. - Severe hypotension: marked drop in blood pressure. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Hepatic impairment: elevated liver enzymes in susceptible individuals. - Opioid withdrawal symptoms: rare, may occur if naloxone effect becomes systemic.

When prescribing Oxycodon / Naloxon Krugmann, clinicians should consider patient‑specific factors and monitor for adverse events.

- Assess pain severity and opioid tolerance: ensure appropriate indication before initiating therapy. - Evaluate gastrointestinal history: patients with severe constipation may benefit most. - Monitor for respiratory depression: especially in opioid‑naïve individuals or when combined with sedatives. - Adjust dose in hepatic or renal impairment: reduced clearance may increase exposure. - Avoid use in patients with known hypersensitivity to either component. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Oxycodone/naloxone can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Concurrent CNS depressants (e.g., benzodiazepines, barbiturates): heightened risk of respiratory depression and profound sedation. - MAO inhibitors: may precipitate severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase oxycodone plasma levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce analgesic effect. - Anticholinergic agents: may exacerbate constipation despite naloxone component. - Diuretics: potential for additive hypotensive effect. - Serotonergic drugs: monitor for serotonin syndrome signs.